← Back to Clinical Trials
Recruiting Phase 3 NCT06669611
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Trial Parameters
Condition Nasopharyngeal Cancinoma (NPC)
Sponsor Sun Yat-sen University
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 242
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-11-27
Completion 2027-11-20
Interventions
Camrelizumab combined GP chemotherapyCamrelizumab combined TPC chemotherapy
Brief Summary
We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.
Eligibility Criteria
Inclusion Criteria: 1. Age over 18 years. 2. ECOG score of 0-1. 3. Expected survival of at least 12 weeks. 4. Recurrent/Metastatic Nasopharyngeal Carcinoma. 5. At least 4 weeks since the previous chemotherapy. 6. At least one (according to RECIST) measurable lesion, lesions that have been previously irradiated can not be considered target lesions. 7. had adequate organ function
Related Trials
NCT07067268
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Rad
View Trial →
NCT06676722
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyn
View Trial →
NCT07232680
Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chem
View Trial →